Director's dealing

RNS Number : 2973W
OptiBiotix Health PLC
31 July 2018
 

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

Director's dealing

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care was notified on 30 July 2018 that Neil Davidson, Non-Executive Chairman of the Company, acquired 103,000 ordinary shares in the Company on 30 July 2018, representing 0.12% of the Company's issued share capital, at a price of 98.6 pence per share.

 

Previously to this notification, Mr Davidson held 375,000 ordinary shares in the Company. Therefore Neil Davidson's total shareholding represents 0.6% of the Company's issued share capital.

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 and the person who arranged for release of this announcement on behalf of the Company was Stephen O'Hara, Chief Executive.

 

For further information, please contact:

 

OptiBiotix Health plc

www.optibiotix.com

Stephen O'Hara, Chief Executive

Contact via Walbrook below



Cairn Financial Advisers LLP

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti




finnCap (Broker)

Tel: 020 7220 0500

Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance)


Abigail Wayne (Corporate Broking)




Walbrook PR Ltd

Tel: 020 7933 8780 or optibiotix@walbrookpr.com

Anna Dunphy

Mob: 07876 741 001

 

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease. 

 

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes. 

 

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits.

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Neil Davidson

2

Reason for notification


a.

Position/Status

Non-Executive Chairman

b.

Initial notification/

Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

OptiBiotix Health plc

b.

LEI

213800UKYQFT941QHS14

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code


Ordinary shares

 

ISIN: GB00BP0RTP38

b.

Nature of the transaction

 Purchase of ordinary shares

c.

Price(s) and volume(s)







Price(s) per share

Volume(s)


 

98.6 pence

 

103,000


 

 

d.

Aggregated information

 

- Aggregated Volume

 

- Price

 

 

103,000

 

98.6 pence

e.

Date of the transaction

30 July 2018

f.

Place of the transaction

AIM

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHKFLBXVDFBBBL
UK 100

Latest directors dealings